We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Production Still On Hold at Emergent’s Bayview Facility as FDA Considers 483 Response
Production Still On Hold at Emergent’s Bayview Facility as FDA Considers 483 Response
Manufacturing of Johnson & Johnson (J&J)’s COVID-19 vaccine at Emergent BioSolutions’ Bayview, Md., plant remains on pause as the FDA assesses the company’s response to troubling observations by agency officials at the facility last month.